Chinese companies Shanghai Lee Kai Technology Co., Ltd (Kai Medtech) and Hangzhou Yangshun Medical Technology Co., Ltd have entered into a collaboration for the market promotion and application of Yangshun’s polyvinyl alcohol embolization microspheres. The financial terms of the agreement were not disclosed.
Collaboration Details
The partnership aims to accelerate the clinical application of home-grown high-end embolization consumables in tumor intervention therapy. It also seeks to support the innovative development of pan-vascular intervention technology. Lee Kai, founded in 2019, specializes in neurological intervention with a product pipeline covering bleeding, ischemic, and pathway devices.
Company Backgrounds
Lee Kai’s focus on neurological intervention makes it a strong partner for Yangshun, which brings expertise in the development of polyvinyl alcohol embolization microspheres. The collaboration is expected to enhance the market presence of these products in the medical device field.-Fineline Info & Tech
